Johane Le Goff

Dr. Johane Le Goff


Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 October 2023 in Cancers
Verified
Journal Article
Open access
PDF file
JGJohane Le Goff
Johane Le Goff
ADAnne-Sophie Le Duc-Banaszuk
Anne-Sophie Le Duc-Banaszuk
CLCaroline Lefeuvre
Caroline Lefeuvre
APAdeline Pivert
Adeline Pivert
ADAlexandra Ducancelle
Alexandra Ducancelle
FRFranck Rexand-Galais
Franck Rexand-Galais
Self-sampling may improve participation in cervical cancer secondary prevention programs by women who do not respond or respond irregularly when invited to contact a health professional for the collection of a cervical specimen. It could also help resolve access problems in areas with a low physician density. The present qualitative study examined barriers to screening, effective screening strategies, and the advantages and disadvantages of sending women urine or vaginal self-sampling kits in two medically underserved administrative departments in France (Mayenne and Sarthe) showing low cervical screening coverage. As part of the CapU4 randomized trial, a team of psychologists investigated the attitudes and experiences of 59 healthcare professionals (gynecologists, general practitioners, and midwives) through semi-structured interviews. Results indicated that health professionals believe that self-sampling may address the issues of low physician density and underscreening by removing logistical, organizational, financial, and psychological obstacles. They confirmed trust in the use of vaginal self-sampling, with urine self-sampling as an alternative solution (e.g., for women with vaginismus). The health professionals also identified several limitations of the self-sampling kit that will need to be addressed in future screening campaigns (incomplete kit, complex instructions, poor anatomical knowledge, and obesity).

30 May 2024 in Cancers
Verified
Journal Article
Open access
PDF file
JGJohane Le Goff
Johane Le Goff
ADAnne-Sophie Le Duc-Banaszuk
Anne-Sophie Le Duc-Banaszuk
CLCaroline Lefeuvre
Caroline Lefeuvre
APAdeline Pivert
Adeline Pivert
ADAlexandra Ducancelle
Alexandra Ducancelle
FRFranck Rexand-Galais
Franck Rexand-Galais
Cervical cancer (CC) was diagnosed in 3159 women in France in 2023, and 1117 died from it. Organized screening for cervical cancer is potentially very effective for participating women. However, reaching under-screened populations remains a major challenge. The present qualitative study explored women’s opinions on what discourages or encourages them to participate in CC screening and assessed the acceptability of two experimental strategies (urinary or vaginal self-sampling kits) to increase the screening coverage in three rural French administrative departments with low medical density and/or low screening participation rates. Forty-eight semi-structured interviews and four focus groups were conducted by a team of psychologists. Results showed that the participants accepted at-home self-sampling to reach non-participating women in medically underserved areas. However, they suggested that the type of kit sent should be adapted to the patient’s profile (embarrassment from earlier exams, cultural aspects, fear of invasiveness, etc.), and that kits should be simple to use (in understandable language taking sociocultural aspects into account). Women wished to be assured that testing on self-samples is accurate and needed information about further actions in case of a positive result.

5 May 2025 in Journal of Infection and Public Health
Verified
Journal Article
Open access
HPHélène De Pauw
Hélène De Pauw
ADAlexandra Ducancelle
Alexandra Ducancelle
MAMarc Arbyn
Marc Arbyn
APAdeline Pivert
Adeline Pivert
ADAnne-Sophie Le Duc-Banaszuk
Anne-Sophie Le Duc-Banaszuk
CLCaroline Lefeuvre
Caroline Lefeuvre
Despite organised screening efforts since 2018 targeting under-screened women, cervical cancer (CC) screening coverage remains moderate (60 %) in France. The target age for HPV-based screening is women aged 30-65. Vaginal self-sampling (VSS) has recently been introduced for women who have not been screened. This study assesses women's perceptions and preferences toward HPV self-sampling among women enrolled in the CapU4 trial. CapU4 is a randomised controlled trial with two experimental arms (mailing either a urine self-sampling (USS) or VSS kit) and a control arm (mailing of a conventional invitation letter). The trial invited 15,000 women aged 30-65, who had no screening test recorded since more than four years and who did not respond to an invitation letter within 12 months before. Half of the women in each arm were randomly selected to receive a supplementary questionnaire (sent in March 2023, with responses collected until August 2023). In total, 682 completed questionnaires were analysed (9.1 % response rate). Most women found self-sampling instructions clear (VSS 87.4 %, USS 90.7 %) and procedures easy (VSS 85.9 %, USS 90.3 %). About 23.5 % of VSS users and 4.9 % of USS users found the process unpleasant. Around 80 % of participants in both SS arms preferred taking a specimen at home rather than going to a health care professional for cervical screening. They also indicated a preference for using self-sampling kit to collect a sample for their next CC screening instead of visiting a health care professional (VSS 82.6 %, USS 89.1 %). Self-sampling appears to be a well-received alternative in women not attending routine CC screening programme.